Immunicon — Investor Presentation (November 2005)
23 slides from Immunicon's investor presentation, Nov 7, 2005

Slide 1: Management Presentation
Management Presentation Cellular Information for Better Healthcare November 2005 Exhibit 99.1

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements that reflect management ’ s current views and opinions as to the status of the Company ’ s products, clinical trials, regulatory approval process, product development, research programs and other future events and op

Slide 3: Immunicon Value Proposition
Immunicon Value Proposition Our products aim to improve cancer disease management Strategic marketing partnership in cancer with J&J (Veridex) Commercialization process well underway – Compelling clinical data – Superior value for health care system – FDA clearances received – J&J executing sales pl

Slide 4: Circulating Tumor Cells as a Real-Time Biopsy Blood Test
Circulating Tumor Cells as a “ Real-Time Biopsy ” Blood Test Most tumors are of epithelial cell origin: Isolation of epithelial cells may mean pan-carcinoma capability Count Phenotype & Genotype Determine Presence Assess Prognosis Direct Therapy Monitor Disease Diagnose Specify Therapy Risk Assessme

Slide 5: CellTracks Technology and Kits
CEC Kit Profile Kit CellTracks ® Technology Circulating Tumor Cell Kit Sample Collection and Preservation Standardized Rare Cell Capture Kits and Marker Reagents for Cell Analysis Endothelial Cell Kit Enrichment Kits for Molecular Analysis Count and Characterize Rare Cells

Slide 6: CTCs: A New Tool to Manage Metastatic Breast Cancer
5 CTCs: A New Tool to Manage Metastatic Breast Cancer 100% 90% 80% 70% 60% 50% 40% 30% % Probability of Survival 20%] 10% 0% <5 CTCs at All Time Points 83 (47%) 1 2 >Bat Baseline &<5CTC atLast Draw 38 (21%) 3 <6 at Early Draw & >5 CTC at Last Draw 17 (10%) >5 CTCs at All Time Points 39 (22%) dvs.2 p

Slide 7: A New Standard for Cancer Disease Management
A New Standard for Cancer Disease Management Future standard: Number, protein expression, and/or gene expression of CTCs better reflects efficacy of treatment Current standard: Radiologist measures changes in lesions on a CT scan to assess tumor burden increase/decrease Objective, quantitative 3-4 w

Slide 8: Significant Clinical Utility of Circulating Tumor Cells
Significant Clinical Utility of Circulating Tumor Cells Early evidence of treatment failure, i.e., change therapy within weeks Predictive at any time point during treatment CTCs predict outcome in patients undergoing chemo & hormonal therapy CTCs predict outcome in non-measurable metastatic breast c

Slide 9: Real-Time Biopsy from a Blood Sample: Her2
Her2 - Her2 + Her2 ++ Her2 +++ Time (weeks) Taxol Herceptin Int J Oncol 21: 1111-1118, 2002 “Real-Time Biopsy” from a Blood Sample Enables selection of targeted therapies

Slide 10: Gene Expression Profiling of Carcinomas
Priority Report, Cancer Research June 15, 2005 13 Breast Cancer Patients 31 Prostate Cancer Patients 30 Colon Cancer Patients 50 Normal Donors Prostate Cancer Breast Cancer Colon Cancer Pan Cancer Hormone refractory Hormone sensitive # CTCs Profile Kit “Real-Time Biopsy” from a Blood Sample Gene Exp

Slide 11: FISH on Rare Cells
Leukocyte Tumor Cell FISH on Rare Cells Chromosome 1 Chromosome 7 Chromosome 8 2 x1, 2 x 7, 2 x 8 3 x1, 5 x 7, 4 x 8

Slide 12: Current Clinical Research and Development Programs
Current Clinical Research and Development Programs Colorectal Cancer – Planned interim analysis encouraging – ~400 patient labeling study in progress (>85% enrolled) Prostate Cancer – Research showed correlation between CTCs and outcome – ~200 patient labeling study in progress (>90% enrolled) Other

Slide 13: Many Product Opportunities
Many Product Opportunities Follow-on applications in cancer – Other settings in cancer (diagnosis, recurrence monitoring,…) – RNA/DNA/protein assays – Detection of tumor cells in bone marrow – Detection of endothelial cells (treatment toxicity, angiogenesis,…) Pharmaceutical development tools (CTCs,

Slide 14: Significant Market Opportunity
Significant Market Opportunity Overall U.S. Market Cancer is the second leading killer – Prevalence: 9.8 million survivors – Incidence: 1.37 million new diagnoses p.a. – Mortality: 570,280 deaths p.a. ~86% of all cancers are carcinomas (solid tumors) – CellSearch ™ System is “ pan - carcinoma ” Canc

Slide 15: Sales and Marketing Strategy
Sales and Marketing Strategy Oncologists Surgeons Pathologists

Slide 16: Strategic Alliance in Cancer with Johnson & Johnson
Strategic Alliance in Cancer with Johnson & Johnson Key elements: Immunicon develops and manufactures J&J finishes, sells and services Revenue shared (~30% to IMMC on reagents) Access to J&J technology, expertise and distribution Reimbursement – J&J responsibility – Existing CPT codes for reimbursem

Slide 17: Commercialization Status
Commercialization Status 33 CellTracks AutoPreps and 38 Cell Analyzers shipped as of 9/30/05 13 CTA IIs and 25 CellSpotters Announced first “CE mark” shipments Customers in the USA, Europe and Japan Customers include reference labs, hospitals, CROs, major Pharma/Biotechs Quest Diagnostics (USA) SRL

Slide 18: Comparison of Estimated Key Economics to Lab & IMMC
~$380 Medicare reimbursement ~$200 Contribution to lab (before labor) ~$50 $175 CellSearch Test ~$127,000 $150,000 Instrumentation Immunicon Lab Comparison of Estimated Key Economics to Lab & IMMC

Slide 19: Capitalization
Capitalization Completed staff/cost reduction in August 2005 Cash burn guidance for 2005 improved to $30 to $32 million Raised $19.7 million in June 2005 Borrowing capacity of $13.6 million @ 9/30/05 (Dollars in thousands) September 30, 2005 December 31, 2004 Cash and cash equivalents 50,085 $ 53,10

Slide 20: Milestones Achieved
Milestones Achieved Publication in New England Journal of Medicine Q3/04 U.S. in vitro diagnostic (IVD) launch Q3/04 Announced deal with Quest Diagnostics Q3/04 Positive interim data in colorectal cancer Q4/04 Commenced clinical trial in prostate cancer Q4/04 Publication in JCO on CTCs in 1 st line

Slide 21: Near-term Milestones (Q4 and Beyond)
Near-term Milestones (Q4 and Beyond) 510(k) for new data in breast cancer Cleared! CellSearch her2neu, EGFR, MUC-1 marker reagents Launched! San Antonio Breast Cancer Symposium Q4/05 Denver Prostate Cancer Biomarker Meeting Q4/05 Bone marrow assay (RUO launch) Q1/2006 Launch first CTC FISH assay (RU

Slide 22: Immunicon Value Proposition
Immunicon Value Proposition Our products aim to improve cancer disease management Strategic marketing partnership in cancer with J&J (Veridex) Commercialization process well underway – Compelling clinical data – Superior value for health care system – FDA clearances received – J&J executing sales pl

Slide 23: Contact Information
3401 Masons Mill Road, Suite 100 Huntingdon Valley, Pennsylvania 19006 * phone 215.830.0777 * fax 215.830.0751 www.immunicon.com Contact Information
Source: SEC EDGAR · 8-K filed Nov 7, 2005
More decks from Immunicon Corp
Investor Presentation (November 2007)29 slides · Nov 2, 2007
Investor Presentation (May 2007)29 slides · May 2, 2007
Investor Presentation (November 2006)26 slides · Nov 2, 2006
Investor Presentation (September 2006)26 slides · Sep 26, 2006
Investor Presentation (August 2006)25 slides · Aug 14, 2006
Investor Presentation (June 2006)27 slides · Jun 2, 2006